Smith+Nephew personalizes robotic-assisted surgery for patients and surgeons with launch of CORIOGRAPH™ Pre-Operative Planning and Modeling Services exclusively for the CORI™ Surgical System
12 Giugno 2024 - 2:00PM
UK Regulatory
Smith+Nephew personalizes robotic-assisted surgery for patients and
surgeons with launch of CORIOGRAPH™ Pre-Operative Planning and
Modeling Services exclusively for the CORI™ Surgical System
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, today announces the launch of its new CORIOGRAPH
Pre-Operative Planning and Modeling Services, providing an
unparalleled, personalized solution for surgeons and patients
across partial and total knee arthroplasty procedures. It is
exclusively for use with the CORI Surgical System - the only
orthopaedic robotic-assisted system to offer either intraoperative
image-free or image-based registration, enabling the surgeon to
choose whether or not to perform a pre-operative MRI scan.
Delivering solutions for differing patient types coupled with
planning and execution tools is essential to personalizing surgery.
Robotic-assisted surgery can improve accuracy and reproducibility,
and may lead to better patient outcomes compared to conventional
techniques.1-3
The first procedures using CORIOGRAPH Pre-Operative Planning and
Modeling Services and RI.KNEE ROBOTICS 3.0 Software were recently
completed by Dr. Steven Haas, Orthopaedic Surgeon and Chief of Knee
Service at the Hospital for Special Surgery in New York. He stated,
“We are now truly personalizing surgery and advancing efficiencies
with RI.KNEE 3.0 and CORIOGRAPH services. Providing the ability to
choose the right imaging modality represents the next paradigm for
individualized patient care and brings orthopaedic robotics to
another level.”
The CORI Surgical System offers proprietary tools and AI-driven
software across the full suite of procedure solutions to deliver a
robotics platform that is flexible and scalable across joint
arthroplasty indications. Built on 15+ years of clinical expertise
and over 350,000 image-based surgery plans, CORIOGRAPH
Pre-Operative Planning and Modeling Services is where the surgical
journey begins. It is designed to optimize procedures and enable
intraoperative efficiencies in conjunction with new RI.KNEE
ROBOTICS 3.0 Software, which includes:
- Image-agnostic registration functionality, including
image-based and image-free offerings
- Optimized knee offering with support for pre-cut tensioning
with the CORI Digital Tensioner for partial, total and revision
knees
“The introduction of CORIOGRAPH Pre-Operative Planning and
Modeling Services signals the next big step in personalized surgery
and the evolution of our robotics ecosystem. This combined with the
CORI Digital Tensioner will further advance efficiencies for
robotic-assisted procedures,” said Mayank Shandil, SVP, Global
Marketing – Reconstruction and Robotics at Smith+Nephew.
To learn more about the CORI Surgical System and Smith+Nephew’s
digital surgery applications across a range of joint arthroplasty
indications, please visit
https://www.smith-nephew.com/en/health-care-professionals/products/orthopaedics/cori
- ends –
Enquiries
Media
Dave Snyder +1
(978) 749-1440
Smith+Nephew
david.snyder@smith-nephew.com
References
- Matsumoto T, Nakano N, Hayashi S, et al. Prosthetic
orientation, limb alignment, and soft tissue balance with
bi-cruciate stabilized total knee arthroplasty: a comparison
between the handheld robot and conventional techniques.
International Orthopaedics 2023;47(6):1473-80. doi:
10.1007/s00264-023-05737-6
- Crizer MP, Haffar A, Battenberg A, et al. Robotic Assistance in
Unicompartmental Knee Arthroplasty Results in Superior Early
Functional Recovery and Is More Likely to Meet Patient
Expectations. Advances in Orthopedics 2021;2021 doi:
10.1155/2021/4770960
- Negrín R, Duboy J, Iñiguez M, et al. Robotic-assisted vs
conventional surgery in medial unicompartmental knee arthroplasty:
a clinical and radiological study. Knee Surg Relat Res
2021;33(1):5. doi: 10.1186/s43019-021-00087-2 [published Online
First: 2021/02/14]
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that
may or may not prove accurate. For example, statements regarding
expected revenue growth and trading profit margins, market trends
and our product pipeline are forward-looking statements. Phrases
such as "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. For Smith+Nephew, these factors include:
conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting
healthcare providers, payers and customers; price levels for
established and innovative medical devices; developments in medical
technology; regulatory approvals, reimbursement decisions or other
government actions; product defects or recalls or other problems
with quality management systems or failure to comply with related
regulations; litigation relating to patent or other claims; legal
and financial compliance risks and related investigative, remedial
or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F, which is available on the SEC’s
website at www. sec.gov, for a discussion of certain of these
factors. Any forward-looking statement is based on information
available to Smith+Nephew as of the date of the statement. All
written or oral forward-looking statements attributable to
Smith+Nephew are qualified by this caution. Smith+Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in
Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain
marks registered in US Patent and Trademark Office.
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Dic 2023 a Dic 2024